Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cyriel Ponsioen

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 26, 2015
Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn's DiseaseGeert D'Haens, Mark Löwenberg, Mark A Samaan, et al.
Hepatology (Baltimore, Md.)|December 17, 2025
Reply: Competing risk and surveillance thresholds for HCC in Patients with PSCMagnus Holmer, Michael Ingre, Martti Färkkilä, et al.
Hepatology (Baltimore, Md.)|April 16, 2025
Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort studyMagnus Holmer, Michael Ingre, Martti Färkkilä, et al.
Journal of Gastroenterology|June 15, 2026
The longstanding issue of the benefit of ursodeoxycholic acid in primary sclerosing cholangitis: a long-term population-based studyBregje Mol, Kim van Munster, Rinse Weersma, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 5, 2013
Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agentsChristine Kestens, Martijn G H van Oijen, Charlotte L J Mulder, et al.
BMJ Open|June 26, 2024
Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitisNasir Hussain, Christopher Ma, Gideon Hirschfield, et al.
Hepatology International|October 4, 2016
Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challengeSerge J Zweers, Elisabeth M de Vries, Martin Lenicek, et al.
Gastroenterology|October 8, 2020
Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled TrialElsemieke de Vries, Ruth Bolier, Jorn Goet, et al.
Alimentary Pharmacology & Therapeutics|July 23, 2022
Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseasesAdriaan Volkers, Tessa Straatmijer, Marjolijn Duijvestein, et al.
United European Gastroenterology Journal|July 22, 2025
Adherence to United European Gastroenterology Guidelines on Diagnosis and Therapy of Immunoglobulin-G4-Related Digestive DiseaseMiroslav Vujasinovic, Marco Lanzillotta, Emma L Culver, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 26, 2015
Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn's DiseaseGeert D'Haens, Mark Löwenberg, Mark A Samaan, et al.
Hepatology (Baltimore, Md.)|December 17, 2025
Reply: Competing risk and surveillance thresholds for HCC in Patients with PSCMagnus Holmer, Michael Ingre, Martti Färkkilä, et al.
Hepatology (Baltimore, Md.)|April 16, 2025
Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort studyMagnus Holmer, Michael Ingre, Martti Färkkilä, et al.
Journal of Gastroenterology|June 15, 2026
The longstanding issue of the benefit of ursodeoxycholic acid in primary sclerosing cholangitis: a long-term population-based studyBregje Mol, Kim van Munster, Rinse Weersma, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 5, 2013
Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agentsChristine Kestens, Martijn G H van Oijen, Charlotte L J Mulder, et al.
BMJ Open|June 26, 2024
Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitisNasir Hussain, Christopher Ma, Gideon Hirschfield, et al.
Hepatology International|October 4, 2016
Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challengeSerge J Zweers, Elisabeth M de Vries, Martin Lenicek, et al.
Gastroenterology|October 8, 2020
Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled TrialElsemieke de Vries, Ruth Bolier, Jorn Goet, et al.
Alimentary Pharmacology & Therapeutics|July 23, 2022
Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseasesAdriaan Volkers, Tessa Straatmijer, Marjolijn Duijvestein, et al.
United European Gastroenterology Journal|July 22, 2025
Adherence to United European Gastroenterology Guidelines on Diagnosis and Therapy of Immunoglobulin-G4-Related Digestive DiseaseMiroslav Vujasinovic, Marco Lanzillotta, Emma L Culver, et al.
Pageof 4